Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Andras Heczey, Amy N. Courtney, Antonino Montalbano, et al.
Nature Medicine (2020) Vol. 26, Iss. 11, pp. 1686-1690
Open Access | Times Cited: 202

Showing 1-25 of 202 citing articles:

Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson, Marcela V. Maus
Nature reviews. Cancer (2021) Vol. 21, Iss. 3, pp. 145-161
Open Access | Times Cited: 600
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner, Sneha Ramakrishna, Kristen W. Yeom, et al.
Nature (2022) Vol. 603, Iss. 7903, pp. 934-941
Open Access | Times Cited: 539
Interleukins in cancer: from biology to therapy
Daria Briukhovetska, Janina Dörr, Stefan Endres, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 8, pp. 481-499
Open Access | Times Cited: 515
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 300
Advancing therapy for neuroblastoma
Bo Qiu, Katherine K. Matthay
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 8, pp. 515-533
Closed Access | Times Cited: 199
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner, Enrico Fritsche, Michael A. Pulsipher, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 379-393
Open Access | Times Cited: 196
From bench to bedside: the history and progress of CAR T cell therapy
Aroshi Mitra, Amrita Barua, Luping Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 152
The landscape of bispecific T cell engager in cancer treatment
Yingtang Zhou, Ming‐Guo Liu, Fei Ren, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 145
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology
Judith Wienke, Miranda P. Dierselhuis, Godelieve A.M. Tytgat, et al.
European Journal of Cancer (2020) Vol. 144, pp. 123-150
Open Access | Times Cited: 137
Advances in Universal CAR-T Cell Therapy
Haolong Lin, Jiali Cheng, Wei Mu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 133
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
Koichi Hirabayashi, Hongwei Du, Yang Xu, et al.
Nature Cancer (2021) Vol. 2, Iss. 9, pp. 904-918
Open Access | Times Cited: 111
Allogeneic CAR Cell Therapy—More Than a Pipe Dream
Kenneth J. Caldwell, Stephen Gottschalk, Aimee C. Talleur
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 99
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Andras Heczey, Xin Xu, Amy N. Courtney, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1379-1388
Closed Access | Times Cited: 80
Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
Nora Berois, Álvaro Pittini, Eduardo Osinaga
Cancers (2022) Vol. 14, Iss. 3, pp. 645-645
Open Access | Times Cited: 71
Challenges and new technologies in adoptive cell therapy
Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 63
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies
Jue Zhang, Sarah Webster, Bret Duffin, et al.
Stem Cell Reports (2023) Vol. 18, Iss. 2, pp. 585-596
Open Access | Times Cited: 45
Advancing cell-based cancer immunotherapy through stem cell engineering
Yan-Ruide Li, Zachary Spencer Dunn, Yanqi Yu, et al.
Cell stem cell (2023) Vol. 30, Iss. 5, pp. 592-610
Open Access | Times Cited: 40
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Kaveh Hadiloo, Safa Tahmasebi, Abdolreza Esmaeilzadeh
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 40
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 27
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Elisa Landoni, Mark G. Woodcock, Gabriel A. Barragán, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 19
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method
Yan-Ruide Li, Yang Zhou, Jiaji Yu, et al.
Nature Biotechnology (2024)
Open Access | Times Cited: 16
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
Yan-Ruide Li, Yang Zhou, Jiaji Yu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1849-1874
Open Access | Times Cited: 13
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
Matthew Bell, Stephen Gottschalk
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 88
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Adam Nelson, Jordan D. Lukacs, Brent Johnston
Cancers (2021) Vol. 13, Iss. 20, pp. 5174-5174
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top